Apellis Pharmaceuticals to Present at Upcoming Investor Conferences
Apellis Pharmaceuticals (NASDAQ: APLS) has announced its participation in two upcoming investor conferences in May 2025. The company will participate in a fireside chat at the BofA Securities 2025 Healthcare Conference on May 13 at 8:40 a.m. PT, and another fireside chat at the Stifel 2025 Virtual Ophthalmology Forum on May 27 at 2:30 p.m. ET. Both events will be webcast live and available on the company's website under the "Events and Presentations" page, with replays accessible for approximately 90 days after the events.
Apellis Pharmaceuticals (NASDAQ: APLS) ha annunciato la sua partecipazione a due conferenze per investitori previste a maggio 2025. L'azienda prenderà parte a una chiacchierata informale al BofA Securities 2025 Healthcare Conference il 13 maggio alle 8:40 PT, e a un'altra chiacchierata informale al Stifel 2025 Virtual Ophthalmology Forum il 27 maggio alle 14:30 ET. Entrambi gli eventi saranno trasmessi in diretta streaming e disponibili sul sito web della società nella pagina "Eventi e Presentazioni", con le registrazioni accessibili per circa 90 giorni dopo gli eventi.
Apellis Pharmaceuticals (NASDAQ: APLS) ha anunciado su participación en dos próximas conferencias para inversores en mayo de 2025. La compañía participará en una charla informal en el BofA Securities 2025 Healthcare Conference el 13 de mayo a las 8:40 a.m. PT, y en otra charla informal en el Stifel 2025 Virtual Ophthalmology Forum el 27 de mayo a las 2:30 p.m. ET. Ambos eventos serán transmitidos en vivo por internet y estarán disponibles en la página web de la empresa bajo la sección "Eventos y Presentaciones", con repeticiones accesibles durante aproximadamente 90 días después de los eventos.
Apellis Pharmaceuticals (NASDAQ: APLS)는 2025년 5월에 열리는 두 개의 투자자 콘퍼런스에 참여한다고 발표했습니다. 회사는 5월 13일 오전 8시 40분(태평양 시간)에 열리는 BofA Securities 2025 Healthcare Conference에서 파이어사이드 채팅에 참여하며, 5월 27일 오후 2시 30분(동부 시간)에 열리는 Stifel 2025 Virtual Ophthalmology Forum에서도 또 다른 파이어사이드 채팅에 참여할 예정입니다. 두 행사 모두 실시간 웹캐스트로 중계되며 회사 웹사이트의 "이벤트 및 프레젠테이션" 페이지에서 시청할 수 있고, 행사 후 약 90일간 다시보기 서비스가 제공됩니다.
Apellis Pharmaceuticals (NASDAQ : APLS) a annoncé sa participation à deux conférences pour investisseurs prévues en mai 2025. La société prendra part à une discussion informelle lors du BofA Securities 2025 Healthcare Conference le 13 mai à 8h40 PT, ainsi qu’à une autre discussion informelle lors du Stifel 2025 Virtual Ophthalmology Forum le 27 mai à 14h30 ET. Les deux événements seront diffusés en direct sur le site web de la société, dans la rubrique « Événements et Présentations », avec des rediffusions disponibles pendant environ 90 jours après les événements.
Apellis Pharmaceuticals (NASDAQ: APLS) hat seine Teilnahme an zwei bevorstehenden Investorenkonferenzen im Mai 2025 bekanntgegeben. Das Unternehmen wird am 13. Mai um 8:40 Uhr PT an einem Fireside Chat auf der BofA Securities 2025 Healthcare Conference teilnehmen und am 27. Mai um 14:30 Uhr ET an einem weiteren Fireside Chat auf dem Stifel 2025 Virtual Ophthalmology Forum. Beide Veranstaltungen werden live per Webcast übertragen und sind auf der Unternehmenswebsite unter der Seite "Events and Presentations" verfügbar, mit Wiederholungen, die etwa 90 Tage nach den Veranstaltungen zugänglich sind.
- None.
- None.
WALTHAM, Mass., May 06, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the company will participate in the following May investor conferences:
- BofA Securities 2025 Healthcare Conference: Fireside chat on Tuesday, May 13, 2025 at 8:40 a.m. PT
- Stifel 2025 Virtual Ophthalmology Forum: Fireside chat on Tuesday, May 27, 2025 at 2:30 p.m. ET
The live conference webcasts will be posted on the “Events and Presentations” page of the “Investors and Media” section of the company’s website. A replay of the webcasts will be available for approximately 90 days following the event.
About Apellis
Apellis Pharmaceuticals, Inc. is a global biopharmaceutical company that combines courageous science and compassion to develop life-changing therapies for some of the most challenging diseases patients face. We ushered in the first new class of complement medicine in 15 years and now have two approved medicines targeting C3. These include the first-ever therapy for geographic atrophy, a leading cause of blindness around the world. We believe we have only begun to unlock the potential of targeting C3 across many serious diseases. For more information, please visit http://apellis.com or follow us on Twitter and LinkedIn.
Investor Contact:
Neil Carnahan
neil.carnahan@apellis.com
207.318.4494
FAQ
When is Apellis Pharmaceuticals (APLS) presenting at the BofA Securities Healthcare Conference in 2025?
What time is Apellis Pharmaceuticals' presentation at the Stifel Virtual Ophthalmology Forum 2025?
How long will the webcasts of Apellis Pharmaceuticals' May 2025 investor conferences be available?
Where can I watch Apellis Pharmaceuticals' (APLS) May 2025 investor conference presentations?
